EAACI Launches Global Antibiotic Allergy Awareness Campaign at EAACI Congress 2025
A Global Call to Action
Antibiotic allergy mislabelling affects millions worldwide. Inaccurate labels lead to avoidance of first-line treatments and overuse of second-line antibiotics, fuelling AMR. EAACI calls on all stakeholders to promote accurate diagnosis and responsible antibiotic use.
'We are launching a movement — not a moment,' said Maria Torres, EAACI President. 'Too many lives are impacted by unverified allergy labels that limit treatment options and worsen health outcomes. This campaign builds momentum to correct labels, improve safety, and preserve antibiotics for future generations. Correcting labels means saving lives — now and in the future.'
The Campaign's Objectives:
Raise awareness about the dangers of incorrect antibiotic allergy labels
Empower patients and healthcare professionals with tools and training
Promote evidence-based allergy evaluation protocols
Encourage rational antibiotic prescribing to protect long-term efficacy
Breaking Down the Barriers
Many patients carry outdated, unverified, or self-reported allergy labels, reducing treatment options and increasing risk. The campaign tackles these issues through education, training, and advocacy.
Resources to Drive Change
A central feature of the campaign is a short educational video explaining antibiotic allergy and why correct labels matter. The Promotional Kit 2025 offers tools to amplify the campaign across all platforms.
Join the Movement
Launched under the slogan 'Correct Labels, Better Lives,' the campaign invites professionals, educators, institutions, and individuals to join the global awareness effort. Together, we can protect the effectiveness of antibiotics.
Explore the campaign and download resources: https://eaaci.org/eaaci-antibiotic-allergy-awareness-campaign/
About EAACI
The European Academy of Allergy and Clinical Immunology (EAACI) is Europe's largest professional association in the field, committed to advancing research and care for those affected by allergic diseases.
Learn more: https://eaaci.org
Contact: communications@eaaci.org | +41 44 205 55 33
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/f2d7cd4b-652b-4207-9c07-315528446450Sign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
7 hours ago
- Medscape
AI Detects Missed Interval Breast Cancer on Mammograms
TOPLINE: An artificial intelligence (AI) system flagged high-risk areas on mammograms for potentially missed interval breast cancers (IBCs), which radiologists had also retrospectively identified as abnormal. Moreover, the AI detected a substantial number of IBCs that manual review had overlooked. METHODOLOGY: Researchers conducted a retrospective analysis of 119 IBC screening mammograms of women (mean age, 57.3 years) with a high breast density (Breast Imaging Reporting and Data System [BI-RADS] c/d, 63.0%) using data retrieved from Cancer Registries of Eastern Switzerland and Grisons-Glarus databases. A recorded tumour was classified as IBC when an invasive or in situ BC was diagnosed within 24 months after a normal screening mammogram. Three radiologists retrospectively assessed the mammograms for visible signs of BC, which were then classified as either potentially missed IBCs or IBCs without retrospective abnormalities on the basis of consensus conference recommendations of radiologists. An AI system generated two scores (a scale of 0 to 100): a case score reflecting the likelihood that the mammogram currently harbours cancer and a risk score estimating the probability of a BC diagnosis within 2 years. TAKEAWAY: Radiologists classified 68.9% of IBCs as those having no retrospective abnormalities and assigned significantly higher BI-RADS scores to the remaining 31.1% of potentially missed IBCs (P < .05). Potentially missed IBCs received significantly higher AI case scores (mean, 54.1 vs 23.1; P < .05) and were assigned to a higher risk category (48.7% vs 14.6%; P < .05) than IBCs without retrospective abnormalities. Of all IBC cases, 46.2% received an AI case score > 25, 25.2% scored > 50, and 13.4% scored > 75. Potentially missed IBCs scored widely between low and high risk and case scores, whereas IBCs without retrospective abnormalities scored low case and risk scores. Specifically, 73.0% of potentially missed IBCs vs 34.1% of IBCs without retrospective abnormalities had case scores > 25, 51.4% vs 13.4% had case scores > 50, and 29.7% vs 6.1% had case scores > 75. IN PRACTICE: "Our research highlights that an AI system can identify BC signs in relevant portions of IBC screening mammograms and thus potentially reduce the number of IBCs in an MSP [mammography screening program] that currently does not utilize an AI system," the authors of the study concluded, adding that "it can identify some IBCs that are not visible to humans (IBCs without retrospective abnormalities)." SOURCE: This study was led by Jonas Subelack, Chair of Health Economics, Policy and Management, School of Medicine, University of St. Gallen, St. Gallen, Switzerland. It was published online on August 04, 2025, in European Radiology. LIMITATIONS: The retrospective study design inherently limited causal conclusions. Without access to diagnostic mammograms or the detailed position of BC, researchers could not evaluate whether AI-marked lesions corresponded to later detected BCs. DISCLOSURES: This research was funded by the Cancer League of Eastern Switzerland. One author reported receiving consulting and speaker fees from iCAD. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Yahoo
12 hours ago
- Yahoo
EAACI Launches Global Antibiotic Allergy Awareness Campaign at EAACI Congress 2025
ZURICH, Aug. 15, 2025 (GLOBE NEWSWIRE) -- EAACI has launched its Antibiotic Allergy Awareness Campaign during its 2025 Congress in Glasgow. The initiative begins a global effort to address mislabelling and its link to antimicrobial resistance (AMR). A Global Call to Action Antibiotic allergy mislabelling affects millions worldwide. Inaccurate labels lead to avoidance of first-line treatments and overuse of second-line antibiotics, fuelling AMR. EAACI calls on all stakeholders to promote accurate diagnosis and responsible antibiotic use. 'We are launching a movement — not a moment,' said Maria Torres, EAACI President. 'Too many lives are impacted by unverified allergy labels that limit treatment options and worsen health outcomes. This campaign builds momentum to correct labels, improve safety, and preserve antibiotics for future generations. Correcting labels means saving lives — now and in the future.' The Campaign's Objectives: Raise awareness about the dangers of incorrect antibiotic allergy labels Empower patients and healthcare professionals with tools and training Promote evidence-based allergy evaluation protocols Encourage rational antibiotic prescribing to protect long-term efficacy Breaking Down the Barriers Many patients carry outdated, unverified, or self-reported allergy labels, reducing treatment options and increasing risk. The campaign tackles these issues through education, training, and advocacy. Resources to Drive Change A central feature of the campaign is a short educational video explaining antibiotic allergy and why correct labels matter. The Promotional Kit 2025 offers tools to amplify the campaign across all platforms. Join the Movement Launched under the slogan 'Correct Labels, Better Lives,' the campaign invites professionals, educators, institutions, and individuals to join the global awareness effort. Together, we can protect the effectiveness of antibiotics. Explore the campaign and download resources: About EAACI The European Academy of Allergy and Clinical Immunology (EAACI) is Europe's largest professional association in the field, committed to advancing research and care for those affected by allergic diseases. Learn more: Contact: communications@ | +41 44 205 55 33 A photo accompanying this announcement is available at in to access your portfolio
Yahoo
2 days ago
- Yahoo
Basilea announces in-licensing of a novel clinical phase 3-ready oral antibiotic
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, August 14, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that it has entered into an exclusive license agreement with Venatorx Pharmaceuticals, Inc., to acquire the global rights to ceftibuten-ledaborbactam etzadroxil, a clinical phase 3-ready oral beta-lactam/beta-lactamase inhibitor (BL/BLI) combination for the potential treatment of complicated urinary tract infections (cUTI), including pyelonephritis. Ceftibuten-ledaborbactam etzadroxil is the combination of ceftibuten, an orally bioavailable cephalosporin antibiotic, and ledaborbactam etzadroxil, the orally bioavailable prodrug of the novel beta-lactamase inhibitor ledaborbactam. The combination demonstrates bactericidal activity against Enterobacterales, including multidrug-resistant pathogens, the major cause of cUTI.[1] In the USA, cUTI account for more than 600,000 hospital admissions each year.[2] This underscores the significant clinical burden and need for effective oral treatment options, which may shorten or entirely avoid hospitalization. In preclinical and clinical phase 1 studies, ceftibuten and ledaborbactam etzadroxil were shown to be safe and well tolerated.[3] David Veitch, Chief Executive Officer of Basilea, said: 'This agreement allows us to strengthen our late-stage clinical pipeline and supports our strategy of ensuring that we have a continuous stream of potential new product launches in the near-term future, positioning us for sustainable substantial revenue growth. Ceftibuten-ledaborbactam etzadroxil holds strong promise in addressing the critical unmet need for the oral treatment of cUTI caused by multidrug-resistant Gram-negative bacteria and represents a compelling global commercial opportunity. We expect starting a registrational phase 3 program in cUTI in about 18 months.' Under the terms of the agreement, Basilea will make an upfront payment and potential milestone payments in 2025. Following the successful completion of the phase 3 clinical development program and after the grant of regulatory approval and start of commercialization, Venatorx is eligible to receive tiered mid-single-digit royalties and additional potential milestone payments of up to USD 325 million in total, if all agreed commercial milestone events are triggered over the term of the contract. The transaction is expected to result in approximately CHF 15 million of additional research and development expenses in 2025, including the full upfront payment, all potential pre-commercial milestone payments and expected R&D expenses in 2025. Basilea will provide updated financial guidance for the full-year 2025, reflecting this transaction, with the half-year earnings report on August 19, 2025. About beta-lactam/beta-lactamase inhibitor (BL/BLI) combinations Many Gram-negative bacteria express enzymes such as extended spectrum beta-lactamases (ESBL) that confer resistance against commonly used antibiotics. Beta-lactamase inhibitors block these enzymes and restore the activity of beta-lactam antibiotics against initially resistant Gram-negative bacteria, therefore BL/BLI combinations are an important addition to the armamentarium for the treatment of infections by multidrug-resistant bacterial pathogens. About ceftibuten-ledaborbactam etzadroxil Ledaborbactam etzadroxil is the orally bioavailable prodrug of ledaborbactam, a novel broad-spectrum boronic acid beta-lactamase inhibitor, which is being developed in combination with ceftibuten, an oral cephalosporin antibiotic, which is approved in the US for the treatment of upper and lower respiratory tract infections and for urinary tract infections outside the US. In vitro and in vivo studies demonstrated that ledaborbactam etzadroxil restores the activity of ceftibuten against strains of Enterobacterales expressing Ambler class A extended spectrum beta-lactamases (ESBLs), class C cephalosporinases, and class A and D carbapenemases (KPC and OXA-48, respectively) as well as multidrug-resistant (MDR) Enterobacterales.[4] Ceftibuten-ledaborbactam etzadroxil has been granted Qualified Infectious Disease Product (QIDP) and Fast Track designations by the US Food and Drug Administration (FDA) for cUTI and uncomplicated urinary tract infections. Ceftibuten-ledaborbactam etzadroxil is an investigational drug and is not yet approved in any country for commercial use. About complicated urinary tract infections (cUTI) Complicated UTIs, which include pyelonephritis (kidney infections), are defined as urinary tract infections ascending from the bladder accompanied by local and systemic signs and symptoms and are one of the most common bacterial infections in hospital and community settings. Increasing resistance of bacteria causing complicated urinary tract infections has led to limited availability of effective oral antibiotic treatment options.[1] Currently, there are no approved oral beta-lactam or beta-lactam/beta-lactamase inhibitor combinations that are effective against Enterobacterales expressing Ambler class A ESBLs, class C cephalosporinases, and class A & D serine carbapenemases (KPC and OXA-48). About Venatorx Pharmaceuticals, Inc. Venatorx is a private, late-stage clinical pharmaceutical company focused on improving health outcomes for patients with multidrug-resistant bacterial infections and hard-to-treat viral infections. Venatorx also developed cefepime-taniborbactam, an intravenous-only antibiotic that successfully completed a Phase 3 study in adults with complicated urinary tract infections (cUTI), including pyelonephritis. The ceftibuten-ledaborbactam etzadroxil project has been funded in whole or in part with Federal funds from National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN272201600029C and the Department of Health and Human Services; Office of the Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority, under Contract No. 75A50123C00050. For more information about Venatorx and its anti-infectives portfolio, please visit About Basilea Basilea is a commercial-stage biopharmaceutical company founded in 2000 and headquartered in Switzerland. We are committed to discovering, developing and commercializing innovative drugs to meet the needs of patients with severe bacterial and fungal infections. We have successfully launched two hospital brands, Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of bacterial infections. In addition, we have preclinical and clinical anti-infective assets in our portfolio. Basilea is listed on the SIX Swiss Exchange (SIX: BSLN). Please visit Disclaimer This communication expressly or implicitly contains certain forward-looking statements, such as "believe", "assume", "expect", "forecast", "project", "may", "could", "might", "will" or similar expressions concerning Basilea Pharmaceutica Ltd, Allschwil and its business, including with respect to the progress, timing and completion of research, development and clinical studies for product candidates. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd, Allschwil to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd, Allschwil is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. For further information, please contact: Peer Nils Schröder, PhDHead of Corporate Communications & Investor RelationsBasilea Pharmaceutica International Ltd, Allschwil Hegenheimermattweg 167b4123 AllschwilSwitzerland Phone +41 61 606 1102 E-mail media_relations@ This ad hoc announcement can be downloaded from References T. P. Lodise, T. Chopra, B. H. Nathanson et al. Epidemiology of Complicated Urinary Tract Infections due to Enterobacterales Among Adult Patients Presenting in Emergency Departments Across the United States. Open Forum Infectious Diseases 2022, Jun 24;9(7):ofac315. M. D. Zilberberg, B. H. Nathanson, K. Sulham et al. Descriptive Epidemiology and Outcomes of Hospitalizations With Complicated Urinary Tract Infections in the United States, 2018. Open Forum Infectious Diseases 2022, Jan 10;9(1):ofab591 C. F. de Oliveira, M. B. Dorr, K. Lowe et al. Evaluation of Single and Multiple Dose Safety and Pharmacokinetics of Ledaborbactam Etzadroxil and Ceftibuten-Ledaborbactam Etzadroxil in Healthy Volunteers. Open Forum Infectious Diseases 2025, Jan 29;12(Suppl 1):ofae631.1425 J. A. Karlowsky, M. G. Wise, M. A. Hackel et al. Ceftibuten-Ledaborbactam Activity against Multidrug-Resistant and Extended-Spectrum-β-Lactamase-Positive Clinical Isolates of Enterobacterales from a 2018–2020 Global Surveillance Collection. Antimicrobial Agents and Chemotherapy 2022, Nov 15;66(11):e0093422 Attachment Press release (PDF)Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
